

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Atlas Arteria (ALX)
<b>ABN</b> Atlas Arteria Limited (ACN 141 075 201) (ATLAX) Atlas Arteria International Limited (EC 43828) (ATLIX)

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Graeme Bevans (Director of ATLAX)
<b>Date of last notice</b>	1 March 2022

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	20 May 2022
<b>No. of securities held prior to change</b>	a) Fully Paid Ordinary ALX Stapled Securities ( <b>Ordinary Stapled Securities</b> ): 229,659 b) Performance Rights granted under ALX's Long Term Incentive Plan ( <b>Performance Rights</b> ): 376,522
<b>Class</b>	Restricted Securities granted under ALX's Short Term Incentive Plan ( <b>Restricted Stapled Securities</b> ) & Performance Rights
<b>Number acquired</b>	127,570 Restricted Stapled Securities 202,492 Performance Rights
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil. See "Nature of Change" section below.

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	a) Ordinary Stapled Securities: 229,659 b) Performance Rights: 579,014 c) Restricted Stapled Securities: 127,570
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights granted under ALX's Long Term Incentive Plan and Restricted Stapled Securities granted under ALX's Short Term Incentive Plan, both of which were approved by securityholders at the 2022 AGM held on 10 May 2022.  Further information regarding the terms of the grants is available in Atlas Arteria's 2022 Notices of Meeting, noting that following publication of the Notices of Meeting, changes to the terms of the grant of Performance Rights were announced to the ASX on 21 April 2022.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.